FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound of formula 
, which is a methylhydrofumarate (MHF) prodrug. In formula (I), radicals and symbols have the values specified in the patent claim. The invention also refers to a pharmaceutical composition containing the declared methylhydrofumarate drugs, to using the declared methylhydrofumarate drugs and the pharmaceutical composition containing them, for treating diseases, such as psoriasis, asthma, multiple sclerosis, inflammatory intestinal disease and arthritis, and to a method of treating the above diseases.
EFFECT: higher oral bioavailability and plasma MHF, dimethylfumarate and/or other metabolites.
47 cl, 1 tbl, 54 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT AND PREVENTION OF RESTLESS LEG SYNDROME WITH USING GABA ANALOGUE PRODRUGS | 2004 |
|
RU2458049C2 |
| TREATMENT OR PREVENTION OF RESTLESS LEGS SYNDROME WITH USING PROMEDICINES OF GABA ANALOGUES | 2004 |
|
RU2377234C2 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
| COMPOUNDS AND PHARMACEUTICAL COMPOSITION POSSESSING PROPERTY FOR GROWTH HORMONE RELEASING, METHOD FOR STIMULATION OF SECRETION OF GROWTH HORMONE FROM MAMMAL HYPOPHYSIS | 1999 |
|
RU2298547C2 |
| LEVODOP PRODRUGS, BASED ON THEM COMPOSITIONS AND THEIR APPLICATION | 2005 |
|
RU2365580C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND METHODS OF USING THEM | 2018 |
|
RU2769696C2 |
| TRICYCLIC TRIAZOLIC COMPOUNDS | 2014 |
|
RU2666728C2 |
| COMPOUNDING, WHICH INHIBITES ACTIVITY OF BTK AND/OR JAK3 KINASES | 2014 |
|
RU2650512C2 |
| DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | 2014 |
|
RU2678990C1 |
| β-D-2ʹ-DEOXY-2ʹ-α-FLUORO-2ʹ-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY HCV | 2016 |
|
RU2764767C2 |
